Nordion announced an additional randomized, multi-centre Phase III clinical trial for TheraSphere , Nordion's yttrium-90, or Y-90, glass microsphere treatment for liver cancer. The YES-P trial will be focused primarily in Europe, with additional locations to be identified globally, and is targeting enrolment of about 350 patients at approximately 24 sites. The trial will further evaluate the safety and efficacy of TheraSphere in the treatment of patients with portal vein thrombosis, or PVT, associated with unresectable hepatocellular carcinoma, or HCC, the most common form of primary liver cancer. The trial will follow a two-armed design. In one arm, patients will undergo Y-90 radioembolization treatment with TheraSphere, while patients in the other arm will receive sorafenib.